GlassScriptPhysician profile
Anthony Jay Spencer
NPI 1780794776
$7,428.86
in general payments reported to CMS, 2019-2025
23 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $179 · 2021: $344 · 2022: $2,308 · 2023: $923 · 2024: $1,357 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,138.97 | 2019-2022 | |
| Alcon Vision LLC | $1,206.92 | 2019-2025 | Precision 1, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $639.30 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $619.80 | 2020-2025 | Cequa |
| Coopervision INC. | $572.75 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $360.16 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $213.66 | 2019-2021 | |
| Oyster Point Pharma, INC. | $197.38 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $185.52 | 2021-2024 | |
| Dompe US, INC. | $147.64 | 2025 | Oxervate |
| Rxsight INC | $140.53 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Glaukos Corporation | $132.44 | 2024 | |
| Allergan, INC. | $128.27 | 2019-2022 | |
| Ocular Therapeutix, INC. | $124.99 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $113.13 | 2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.97 | 2022-2023 | |
| Sight Sciences, INC. | $103.09 | 2024 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $99.98 | 2019 | |
| Emd Serono, INC. | $73.99 | 2019 | |
| Abb Con-Cise Optical Group LLC | $51.02 | 2019 | |
| Kala Pharmaceuticals, INC. | $32.66 | 2021 | |
| Abbvie INC. | $28.34 | 2022 | |
| Maculogix, INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.